Rare Disease Research Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Rare Disease Research's estimated annual revenue is currently $7.1M per year.(i)
  • Rare Disease Research's estimated revenue per employee is $155,000

Employee Data

  • Rare Disease Research has 46 Employees.(i)
  • Rare Disease Research grew their employee count by 24% last year.

Rare Disease Research's People

NameTitleEmail/Phone
1
Chief Operating OfficerReveal Email/Phone
2
Chief Technology OfficerReveal Email/Phone
3
Director Human ResourcesReveal Email/Phone
4
Director Clinical Operations, Principal InvestigatorReveal Email/Phone
5
Medical Director RDR-NC, Principal InvestigatorReveal Email/Phone
6
Director, Research Home HealthReveal Email/Phone
7
Principal Investigator, Head ResearchReveal Email/Phone
8
Clinical Research NurseReveal Email/Phone
9
Senior Clinical Research Coordinator/Research EducatorReveal Email/Phone
10
Family Nurse PractitionerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$1.7M11-8%N/AN/A
#3
$2.3M1550%N/AN/A
#4
$1.1M70%N/AN/A
#5
$17.1M1105%$0.07BN/A
#6
$4M26-7%N/AN/A
#7
$0.8M50%N/AN/A
#8
$1.1M717%N/AN/A
#9
$7.8M502%N/AN/A
#10
$1.7M1110%N/AN/A
Add Company

What Is Rare Disease Research?

At Rare Disease Research, we aim to optimize the process of conducting clinical trials in rare disease conditions. To improve access to investigational therapies, increase opportunities for trial participation, patient recruitment and retention, we have an experienced team with multidisciplinary approach to orchestrate clinical research trials in rare disease conditions. We closely collaborate with sponsors, CRO, and patient advocacy groups to improve awareness and recruitment for cutting edge clinical trials. Because rare diseases are not often considered a public health matter, we tirelessly advocate for newborn screenings. We want to improve health outcome for infants with rare genetics conditions who otherwise would have to endure diagnosis odyssey and delayed treatment. Our newborn screening project for Spinal Muscular Atrophy will begin in 2018.

keywords:N/A

N/A

Total Funding

46

Number of Employees

$7.1M

Revenue (est)

24%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.5M467%N/A
#2
$5.3M465%N/A
#3
$5.3M46-16%N/A
#4
$8.1M46-38%N/A
#5
$3.5M460%N/A